Parkinsonism & Related Disorders
Volume 16, Issue 4 , Pages 237-242 , May 2010

Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review

  • L. Correia Guedes

      Affiliations

    • Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon School of Medicine, Lisbon, Portugal
    • Corresponding Author InformationCorresponding author. Tel.: +351 966280324; fax: +351 217976644.
    • ,
  • J.J. Ferreira

      Affiliations

    • Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon School of Medicine, Lisbon, Portugal
    • ,
  • M.M. Rosa

      Affiliations

    • Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon School of Medicine, Lisbon, Portugal
    • ,
  • M. Coelho

      Affiliations

    • Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon School of Medicine, Lisbon, Portugal
    • ,
  • V. Bonifati

      Affiliations

    • Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • C. Sampaio

      Affiliations

    • Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon School of Medicine, Lisbon, Portugal

Received 7 July 2009 ,Revised 6 November 2009 ,Accepted 8 November 2009.

References 

  1. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol. 2002 Mar;51(3):296–301
  2. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595–600
  3. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607
  4. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005;365(9457):412–415
  5. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005 Apr;76(4):672–680
  6. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter C, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005;365:410–412
  7. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005;365:415–416
  8. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson’ disease in Europe: a collaborative study of population based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl. 5):S21–S23
  9. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for LRRK2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan;22(1):55–61
  10. Lesage S, Belarbi S, Troiano A, Condroyer C, Hecham N, Pollak P, et al. Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?. Neurology. 2008 Nov 4;71(19):1550–1552
  11. Goldwurm S, Di Fonzo A, Simons EJ, Rohé CF, Zini M, Canesi M, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet. 2005;42:e65
  12. Lesage S, Leutenegger A-L, Ibanez P, Janin S, Lohmann E, Dürr A, et al. LRRK2 haplotype analyses in European and North African families with Parkinson's disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet. 2005;77:330–332
  13. Zabetian CP, Morino H, Ujike H, Yamamoto M, Oda M, Maruyama H, et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology. 2006;67(4):697–699
  14. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet. 2006 Oct;79:752–758
  15. Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008;14:77–80
  16. Bonifati V. The LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. Eur J Hum Genet. 2006 Oct;14(10):1061–1062
  17. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol. 2005;57:762–765
  18. Carmine Belin A, Westerlund M, Sydow O, Lundstromer K, Hakansson A, Nissbrandt H, et al. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord. 2006 Oct;21(10):1731–1734
  19. Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain. 2005 Dec;128(Pt 12):3000–3011
  20. Schlitter AM, Woitalla D, Mueller T, Epplen JT, Dekomien G. The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany. J Neurol Neurosurg Psychiatry. 2006;77(7):891–892
  21. Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E, et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord. 2006 Sep;21(9):1506–1510
  22. Möller JC, Rissling I, Mylius V, Höft C, Eggert KM, Oertel WH. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease. Eur J Neurol. 2008 Jul;15(7):743–745
  23. Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, et al. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov Disord. 2009 Jan 30;24(2):196–203
  24. Nuytemans K, Rademakers R, Theuns J, Pals P, Engelborghs S, Pickut B, et al. Founder mutation p.R1441C in the Leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur J Hum Genet. 2008;16(4):471–479
  25. Bialecka M, Hui S, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease. Neurosci Lett. 2005;390:1–3
  26. Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, et al. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. Eur J Neurol. 2007 Apr;14(4):413–417
  27. Pchelina SN, Yakimovskii AF, Emelyanov AK, Ivanova ON, Schwarzman AL, Singleton AB. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. Eur J Neurol. 2008 Jul;15(7):692–696
  28. Haubenberger D, Bonelli S, Hotzy C, PLeitner P, Lichtner P, Samal D, et al. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Mov Disord. 2007 Aug 15;22(11):1640–1643
  29. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005;128:2786–2796
  30. Williams-Gray CH, Goris A, Foltyne T, Brown J, Maranian M, Walton A, et al. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. J Neurol Neurosurg Psychiatry. 2006;77:665–667
  31. Gosal D, Ross AO, Wiley J, Irvine GB, Johnston JA, Toft M, et al. Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Parkinsonism Relat Disord. 2005 Sep;11(6):349–352
  32. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol. 2005 Nov;58(5):784–787
  33. Funalot B, Nichols WC, Pérez-Tur J, Mercier G, Lucotte G. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease. Genet Test. 2006 Winter;10(4):290–293
  34. Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol. 2007;64:425–430
  35. Brás JM, Guerreiro RJ, Ribeiro MH, Januário C, Morgadinho A, Oliveira CR, et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord. 2005;20(12):1653–1655
  36. Ferreira JJ, Correia Guedes L, Rosa MM, Coelho M, van Doeselaar M, Di Fonzo A, et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Mov Disord. 2007 Jun 15;22(8):1194–1201
  37. Infante J, Rodriguez E, Combarros O, Mateo I, Fontalba A, Pascual J, et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett. 2006;395:224–226
  38. Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, et al. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol. 2006;13:391–394
  39. Gaig C, Ezquerra M, Marti MJ, Muñoz E, Vallderiola F, Tolosa E. LRRK2 mutations in Spanish patients with Parkinson's disease. Arch Neurol. 2006;63:377–382
  40. González-Fernández MC, Lezcano E, Ross AO, Gómez-Esteban JC, Gómez-Busto F, Velasco F, et al. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord. 2007 Dec;13(8):509–515
  41. Gorostidi A, Ruiz-Martínez J, Lopez de Munain A, Alzualde A, Martí Massó JF. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics. 2009 Apr;10(2):157–159
  42. Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, et al. LRRK2 mutations and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord. 2006 Oct;12(7):410–419
  43. Marongiu R, Guezzi D, Lalongo T, Soleti F, Elia A, Cavone S, et al. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Mov Disord. 2006;21(8):1232–1235
  44. Squillaro T, Cambi F, Ciacci G, Rossi S, Ulivelli M, Malandrini A, et al. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease. J Hum Genet. 2007;52:201–204
  45. Civitelli D, Tarantino P, Nicoletti G, Candiano ICC, Annesi F, Marco EV, et al. LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson's disease. Clin Genet. 2007;71:367–370
  46. De Rosa A, Criscuolo C, Mancini P, De Martino M, Giordano IA, Pappata S, et al. Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy. Parkinsonism Relat Disord. 2009 Mar;15(3):242–244
  47. Cossu G, van Doeselaar M, Deriu M, Melis M, Molari A, Di Fonzo A, et al. LRRK2 mutations and Parkinson's disease in Sardinia – a Mediterranean genetic isolate. Parkinsonism Relat Disord. 2007 Feb;13(1):17–21
  48. Floris G, Cannas A, Solla P, Murru MR, Tranquilli S, Corongiu D, et al. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population. Importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism Relat Disord. 2009 May;15(4):277–280
  49. Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, Johnson J, Papakonstantinou L, Papadimitriou A, et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol. 2007 Jan;14(1):7–11
  50. Kalinderi K, Fidani L, Bostantjopoulou S, Katsarou Z, Kotsis A. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. Eur J Neurol. 2007 Act;14(10):1088–1090
  51. Papapetropoulos S, Adi N, Shehadeh L, Bishopric N, Singer C, Argyriou AA, et al. Is the G2019S LRRK2 mutation common in all southern European populations?. J Clin Neurosci. 2008 Sep;15(9):1027–1030
  52. Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?. Neurology. 2007 Oct 16;69(16):1595–1602
  53. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354(4):422–423
  54. Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, et al. LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study. Lancet Neurol. 2008 Jul;7(7):591–594
  55. Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A, et al. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PloS ONE. 2008;3(10):e3421
  56. Paisán-Ruíz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, et al. LRRK2 gene in Parkinson disease. Mutation analysis and case control association study. Neurology. 2005;65:696–700
  57. Dupré N, Rivière JB, Myers RH, Provencher P, Pourcher E, Émond F, et al. LRRK2 is not a significant cause of Parkinson's disease in French–Canadians. Can J Neurol Sci. 2007;34:333–335
  58. Grimes DA, Racacho L, Han F, Panisset M, Bulman DE. LRRK2 screening in a Canadian Parkinson's disease cohort. Can J Neurol Sci. 2007 Aug;34(3):336–338
  59. Farrer M, Stone J, Mata IF, Lincoln S, Kacergus J, Hulihan M, et al. LRRK2 mutations in Parkinson's disease. Neurology. 2005;65:738–740
  60. Hernandez D, Paisan Ruiz C, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, et al. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett. 2005;389:137–139
  61. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, et al. A clinic-based study of the LRRK2 gene in Parkinson's disease yields new mutations. Neurology. 2005;65:741–744
  62. Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord. 2006;21(4):519–523
  63. Scholz S, Mandel RJ, Fernandez HH, Foote KD, Rodriguez RL, Barton E, et al. LRRK2 mutations in a clinic-based cohort of Parkinson's disease. Eur J Neurol. 2006 Dec;13(12):1298–1301
  64. Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21;251(1–2):102–106
  65. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006;67:1786–1791
  66. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtishch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi jews. N Engl J Med. 2006;354(4):424–425
  67. Johnson J, Paisán-Ruíz C, Lopez G, Crews C, Britton A, Malkani R, et al. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neurodegener Dis. 2007;4(5):386–391
  68. Munhoz RP, Wakutani Y, Marras C, Teive HA, Raskin S, Werneck LC, et al. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. Mov Disord. 2008 Jan 30;23(2):290–294
  69. Pimentel MM, Moura KC, Abdalla CB, Pereira JS, de Rosso AL, Nicaretta DH, et al. A study of LRRK2 mutations and Parkinson's disease in Brazil. Neurosci Lett. 2008 Mar 5;433(1):17–21
  70. Perez-Pastene C, Cobb SA, Díaz-Grez F, Hulihan MM, Miranda M, Venegas P, et al. Lrrk2 mutations in South America: a study of Chilean Parkinson's disease. Neurosci Lett. 2007 Jul 18;422(3):193–197
  71. Mata IF, Cosentino C, Marca V, Torres L, Mazzetti P, Ortega O, et al. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat Disord. 2009 Jun;15(5):370–373
  72. Punia S, Behari M, Govindappa ST, Swaminath PV, Jayaram S, Goyal V, et al. Absence/ rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neurosci Lett. 2006;409:83–88
  73. Lu CS, Simons EJ, Wu-Chou YH, Di Fonzo A, Chang HC, Chen RS, et al. The LRRK2 I2012T, G2019S and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord. 2005;11:521–522
  74. Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, Wu YR. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease. Mov Disord. 2006;21(6):880–881
  75. Lin CH, Tzen KY, Yu CY, Tai CH, Farrer MJ, Wu RM. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. J Biomed Sci. 2008 Sep;15(5):661–667
  76. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics. 2005;6:171–177
  77. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992;32(Suppl.):S125–S127
  78. Farrer MJ, Stone JT, Lin CH, Dächsel JC, Hulihan MM, Haugarvoll K, et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord. 2007;13:89–92
  79. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett. 2005;384(3):327–329
  80. Cho JW, Kim SY, Park SS, Kim HJ, Ahn TB, Kim JM, et al. The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease. Can J Neurol Sci. 2007;34:53–55
  81. Choi JM, Woo MS, Ma HI, Kang SY, Sung YH, Yong SW, et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics. 2008;9:263–269
  82. Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J, et al. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord. 2007 May 15;22(7):982–989
  83. Mellick GD, Siebert GA, Funayama M, Buchanan DD, Li Y, Imamichi Y, et al. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat Disord. 2009 Feb;15(2):105–109
  84. Daniel SE, Lees AJ. Parkinson's disease Society Brain Bank, London: overview and research. J Neural Transm. 1993;39(Suppl.):165–172
  85. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39
  86. Gibb W, Lees A. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745–752
  87. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184
  88. Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol. 2002;51:621–625
  89. Ward C, Gibb W. Research diagnostic criteria for Parkinson's disease. Adv Neurol. 1990;53:245–249
  90. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008 Jul;7(7):583–589

☆ The review of this paper was entirely handled by the Co-Editor-in-Chief, Zbigniew Wszolek.

PII: S1353-8020(09)00276-4

doi: 10.1016/j.parkreldis.2009.11.004

Parkinsonism & Related Disorders
Volume 16, Issue 4 , Pages 237-242 , May 2010

Article Tools

* Image Usage & Resolution